tiprankstipranks
Trending News
More News >
Krebs Biochemicals & Industries Ltd. (IN:KREBSBIO)
:KREBSBIO
India Market
Advertisement

Krebs Biochemicals & Industries Ltd. (KREBSBIO) Stock Statistics & Valuation Metrics

Compare
0 Followers

Total Valuation

Krebs Biochemicals & Industries Ltd. has a market cap or net worth of ₹1.48B. The enterprise value is ―.
Market Cap₹1.48B
Enterprise Value

Share Statistics

Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,560,587
Owned by Insiders
Owned by Institutions

Financial Efficiency

Krebs Biochemicals & Industries Ltd.’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is -18.66%.
Return on Equity (ROE)0.18
Return on Assets (ROA)-0.16
Return on Invested Capital (ROIC)-18.66%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee2.27M
Profits Per Employee-1.41M
Employee Count191
Asset Turnover0.26
Inventory Turnover0.92

Valuation Ratios

The current PE Ratio of Krebs Biochemicals & Industries Ltd. is ―. Krebs Biochemicals & Industries Ltd.’s PEG ratio is -0.15.
PE Ratio
PS Ratio3.37
PB Ratio-1.00
Price to Fair Value-1.00
Price to FCF-12.74
Price to Operating Cash Flow0.00
PEG Ratio-0.15

Income Statement

In the last 12 months, Krebs Biochemicals & Industries Ltd. had revenue of 433.12M and earned -269.39M in profits. Earnings per share was -12.50.
Revenue433.12M
Gross Profit377.56M
Operating Income-217.19M
Pretax Income-269.24M
Net Income-269.39M
EBITDA-143.21M
Earnings Per Share (EPS)-12.50

Cash Flow

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00

Dividends & Yields

Krebs Biochemicals & Industries Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.46
52-Week Price Change-18.66%
50-Day Moving Average74.25
200-Day Moving Average81.02
Relative Strength Index (RSI)42.50
Average Volume (3m)5.43K

Important Dates

Krebs Biochemicals & Industries Ltd. upcoming earnings date is Nov 6, 2025, TBA (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date

Financial Position

Krebs Biochemicals & Industries Ltd. as a current ratio of 0.10, with Debt / Equity ratio of 0.00%
Current Ratio0.10
Quick Ratio0.04
Debt to Market Cap1.45
Net Debt to EBITDA-14.81
Interest Coverage Ratio-3.67

Taxes

In the past 12 months, Krebs Biochemicals & Industries Ltd. has paid 153.00K in taxes.
Income Tax153.00K
Effective Tax Rate>-0.01

Enterprise Valuation

Krebs Biochemicals & Industries Ltd. EV to EBITDA ratio is -24.99, with an EV/FCF ratio of -31.25.
EV to Sales8.26
EV to EBITDA-24.99
EV to Free Cash Flow-31.25
EV to Operating Cash Flow-45.36

Balance Sheet

Krebs Biochemicals & Industries Ltd. has ₹1.42M in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹1.42M billion.
Cash & Marketable Securities₹1.42M
Total Debt₹0.00
Net Cash₹1.42M
Net Cash Per Share₹0.07
Tangible Book Value Per Share-₹68.91

Margins

Gross margin is 87.22%, with operating margin of -50.15%, and net profit margin of -62.20%.
Gross Margin87.22%
Operating Margin-50.15%
Pretax Margin-62.16%
Net Profit Margin-62.20%
EBITDA Margin-33.06%
EBIT Margin-48.51%

Analyst Forecast

The average price target for Krebs Biochemicals & Industries Ltd. is ₹68.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target₹68.00
Price Target Upside-1.85% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-31.91%
EPS Growth Forecast-38.46%

Scores

Smart ScoreN/A
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis